Diagnostics; making a difference

Member Press Releases

Current Articles | Categories | Search | Syndication

22 April 2015  Joanne Hunter
Safe, Easy Specimen Transport System New Triple Universal Pack Extends SpeciSafe® Range
By Joanne Hunter @ 08:09 :: 121 Views

SpeciSafe® secondary packaging containers provide a safe, convenient and economical solution for compliant mailing of biohazardous and clinical specimens. The extensive SpeciSafe range includes solutions for screw cap microtubes, serum vials, vacuum blood collection tubes, cryovials, Bijou containers, swabs/transport tubes and is now extended to include a pack to seal 3 Universal containers in addition to the original single Universal pack.

Read More

08 April 2015  Joanne Hunter
RD Biomed achieves ISO 9001 certification
By Joanne Hunter @ 09:15 :: 96 Views

RD Biomed achieves ISO 9001 certification

Yorkshire medical technology innovator meets global benchmark for quality management



RD Biomed, the Hull-based medical technology company, is proud to announce that its quality management system has achieved the International Organization for Standardization (ISO) 9001:2008 certification.

Read More

02 April 2015  Joanne Hunter
By Joanne Hunter @ 14:27 :: 245 Views

  • Precision test detects minute deterioration in kidney function
  • Identifies patients at early stages – missed by current testing
  • NICE says new test regime could cut the number of patients on medication and dialysis by up to 20%
  • Chronic kidney disease affects older people and more common in women
  • Unchecked, CKD can eventually cause kidney failure and death
  • CKD linked to diabetes, hypertension and cardiovascular disease
Read More

18 March 2015  Joanne Hunter
By Joanne Hunter @ 13:47 :: 154 Views

Cobham, UK, March 18th 2015: Proteome Sciences plc, a global leader in proteomics, is pleased to announce that it will present four posters at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders which opens today in Nice, France. The posters highlight recent developments in Proteome Sciences’ proprietary biomarker discovery technologies for enhanced biomarker discovery, mapping of cell signaling pathways and targeted mass spectrometry methods for a blood biomarker of Alzheimer’s disease.

Read More

09 March 2015  Joanne Hunter
Trading update
By Joanne Hunter @ 12:13 :: 124 Views

9 March 2015: The Board is pleased to announce that its biomarker services division has got off to a good start in 2015 with five biomarker contracts signed. Encouragingly, there has been a strong increase in demand for SysQuant™, TMT® calibrator and TMT® MS3 services from major pharmaceutical customers and this is reflected by a growing pipeline of firm orders and quotations that should close in Q1/Q2.

Read More

09 March 2015  Joanne Hunter
New Philisa® ampC ID Kit Identifies Antibiotic Resistant Gram Negative Bacteria
By Joanne Hunter @ 11:34 :: 289 Views

The new Streck Philisa® ampC ID Kit enables rapid identification of six plasmid-mediated ampC resistance genes for pathogen surveillance in hospitals and research. When used along with standard culture, this conventional PCR kit will help to provide up-to-date information for infection control by identifying which gram-negative ampC resistant bacterial strains are present in the hospital. Resistance to the beta-lactam class of anti-microbials is a significant cause of multidrug-resistant urinary tract and bloodstream infections.

Read More

06 March 2015  Joanne Hunter
GSK-Novartis deal close - Vaccines communication
By Joanne Hunter @ 09:07 :: 161 Views

GlaxoSmithKline plc (GSK) is pleased to announce a three-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines & Oncology Businesses:

  • GSK and novartis will create a new world-leading Consumer Healthcare business in which GSK will have a majority control.
  • GSK will acquire Novartis' global Vaccines business (excluding influenza vaccines).
  • GSK will divest its marketed Oncology portfolio, related R&D activities and rights to its AKT inhibitor and also grant of commercialisation partner rights for future oncology products to Novartis.
Read More

05 March 2015  Joanne Hunter
Siemens combats increasing point-of-care workload with ecosystem approach
By Joanne Hunter @ 12:06 :: 175 Views

Siemens Healthcare Diagnostics is tackling challenges faced by point-of-care (POC) coordinators in the laboratory with an innovative ecosystem approach. The Ecosystem solution was recently launched as an integrated component of the RAPIDComm® Data Management System, an informatics solution which centrally manages Siemens in vitro diagnostics analysers and operators. The solution encompasses eight core components including device management, operator management, quality control, compliance reporting, competency management, inventory management, remote monitoring and mobile access.

Read More

25 February 2015  Joanne Hunter
New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer
By Joanne Hunter @ 13:42 :: 195 Views

Greenville, South Carolina – 25th February 2015 – EKF Diagnostics subsidiary, Selah Genomics, has announced a major, four-way collaboration with Greenville Health System (GHS, South Carolina), DecisionQ Corporation (Virginia), and BD (Becton Dickinson and Company, New Jersey). Expected to last 18 months, the collaboration aims to unite classic clinical annotations with proprietary next generation sequencing (NGS) technology and artificial intelligence-based decision support algorithms in order to improve clinical decision support in the treatment of colon cancer patients. 

Read More

23 February 2015  Joanne Hunter
EKF introduces new diabetic biomarker test – The Stanbio Chemistry GSP LiquiColor® Assay
By Joanne Hunter @ 12:12 :: 189 Views

Cardiff, UK – 19th February 2015 – EKF Diagnostics, the global diagnostics company, announces that it has introduced a new diabetic biomarker test that provides a 2-3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test closes the information gap between daily blood glucose testing and the 2-3 month HbA1c reading. This means that GSP serves as an accurate intermediate marker of glycemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and hemodialysis.1

Read More

Previous Page | Next Page